Cardio Diagnostics Holdings annual r&d spending
2021
2022
2023
2024
2025
Cardio Diagnostics Holdings R&D Spending Growth & History (CDIO)
Cardio Diagnostics Holdings's r&d spending was $641,212 for fiscal 2025.
View full Cardio Diagnostics Holdings company overviewCardio Diagnostics Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $641,212 | $413,246 | +181.28% |
| 2024 | 2024-12-31 | $227,966 | $82,784 | +57.02% |
| 2023 | 2023-12-31 | $145,182 | $104,734 | +258.93% |
| 2022 | 2022-12-31 | $40,448 | $8,980 | +28.54% |
| 2021 | 2021-12-31 | $31,468 | — | — |
Cardio Diagnostics Holdings quarterly r&d spending
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $162,929 | −$15,607 | −8.74% |
| Q1 2026 | 2026-03-31 | $129,776 | $10,992 | +9.25% |
| Q4 2025 | 2025-12-31 | $154,843 | −$49,756 | −24.32% |
| Q3 2025 | 2025-09-30 | $189,049 | $183,802 | +3502.99% |
| Q2 2025 | 2025-06-30 | $178,536 | $171,256 | +2352.42% |
| Q1 2025 | 2025-03-31 | $118,784 | $107,944 | +995.79% |
| Q4 2024 | 2024-12-31 | $204,599 | $197,107 | +2630.90% |
| Q3 2024 | 2024-09-30 | $5,247 | −$33,461 | −86.44% |
| Q2 2024 | 2024-06-30 | $7,280 | −$5,037 | −40.89% |
| Q1 2024 | 2024-03-31 | $10,840 | −$75,825 | −87.49% |
| Q4 2023 | 2023-12-31 | $7,492 | −$23,595 | −75.90% |
| Q3 2023 | 2023-09-30 | $38,708 | $35,518 | +1113.42% |
| Q2 2023 | 2023-06-30 | $12,317 | $7,276 | +144.34% |
| Q1 2023 | 2023-03-31 | $86,665 | $85,535 | +7569.47% |
| Q4 2022 | 2022-12-31 | $31,087 | — | — |
| Q3 2022 | 2022-09-30 | $3,190 | — | — |
| Q2 2022 | 2022-06-30 | $5,041 | — | — |
| Q1 2022 | 2022-03-31 | $1,130 | — | — |
Cardio Diagnostics Holdings r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Cardio Diagnostics Holdings's r&d spending increased from $31,468 to $641,212, a change of $609,744. The latest reported quarter, Q2 2026, shows $162,929.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardio Diagnostics Holdings source filings ↗